Cynthia M Perry-Keaty, FNP, AOCNP
世界博彩公司十大排名提供者
临床利益
- 乳腺癌
- 癌症遗传学
- 癌症生存
- 肺癌
- 姑息治疗
亚洲十大博彩公司排名
教育
- 状态 University of 纽约 at Binghamton, Binghamton, N.Y.
- 埃尔米拉学院，埃尔米拉，n.n.Y.
- Robert Packer Hospital School of Nursing, 塞尔, Pa.
- American Nurses Credentialing Center
- 肿瘤护理学会
- Nurse Practitioner Association
- 美国心脏协会
临床试验
- 一个随机, 非盲, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in 病人 With Triple Negative 乳腺癌 Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive 乳腺癌): COMPASSHER2 Residual Disease (RD), 一个双盲, Phase III Randomized Trial of T-DM1 and Placebo Compared with T
- A021806, A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
- A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
- A151216 ALCHEMIST, Adjuvant 肺癌 Enrichment Marker Identification and Sequencing Trial
- A221805: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in 病人 With Stage II-III Colorectal Cancer
- CAMBRIA-1:第三阶段, 非盲, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, 下一代, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or
- EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
- EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in 病人 with Unresectable Stage III or Stage IV Melanoma
- EA6194, Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in 病人 with Operable Melanoma: Efficacy and Biomarker Study
- FRNM-008 The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
- Interim FDG-PET/CT for PreDIcting REsponse of HER2+ 乳腺癌 to Neoadjuvant Therapy: DIRECT trial
- LungMap (Screening Protocol for Lung-Map):
- NRG-BR007: A Phase III 诊所al Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, 激素敏感, her - 2 -, Oncotype Recurrence Score Less Than or Equal to 18 乳腺癌
- NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
- OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC 病人 Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
- Preserve-003:第三阶段, 两级, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell 肺癌s that Progressed on PD-1/PD-L1 Inhibitors
- S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory 乳腺癌
- S1802, &”;Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer).&”;
病人的评论